Less than emphatic cardiovascular outcomes data leave Lilly looking vulnerable to Novo Nordisk’s competing drugs.
After crashing on a late-stage Alzheimer’s failure last year VTV Therapeutics has taken a small step forward in type 1 diabetes.
An analysis looking at forecast discrepancies for the top pipeline projects reveals vast differences of opinion about Vertex's cystic fibrosis triplet and Novo…
The notoriously secretive German pharma company Boehringer Ingelheim has made much of a new drive towards transparency, but there are still things it would rather keep to…
Today’s deal will see the companies take a triple combination into clinical trials.
Novo Nordisk hopes that its attempt to preserve beta cells will fare better than Caladrius’s, while Aslan tries its hand at DHODH inhibition.
Shares in the company surge after its weekly growth hormone treatment proves superior to daily injections, raising broader hopes for Ascendis’s long-acting technology.
Lilly's authorised Humalog generic price undercuts Sanofi’s copycat attack, but will cut into branded sales.
Climbing consensus sales forecasts for 2022 suggest that last year equity analysts brushed off concerns about pricing restraints.